ISSN 1662-4009 (online)

ey0016.10-12 | (1) | ESPEYB16

10.12. Efficacy of growth hormone treatment in children with type 1 diabetes mellitus and growth hormone deficiency - An analysis of KIGS data

W Bonfig , A Lindberg , M Carlsson , W Cutfield , D Dunger , C Camacho-Hubner , RW Holl

To read the full abstract: J Pediatr. 2018 Jul;198:260–264This study aimed to analyze growth hormone (GH) doses and first-year growth response in prepubertal patients with the combination of type 1 diabetes (T1D) and growth hormone deficiency (GHD).A total of 69 patients with T1D and GHD treated with GH have been enrolled in KIGS (Pfizer International Growth D...

ey0015.4-2 | Important for clinical practice | ESPEYB15

4.2 Efficacy of growth hormone treatment in children with type 1 diabetes mellitus and growth hormone deficiency-an analysis of KIGS data

W Bonfig , A Lindberg , M Carlsson , W Cutfield , D Dunger , C Camacho-Hübner , RW Holl

To read the full abstract: J Pediatr 2018; 198: 260-264The incidence of T1DM in children <15 years is increasing at an overall annual relative rate of 3.9% (95% CI 3.6-4.2) [11]. The prevalence of GHD is estimated at approximately 1:4000 to 1:10000 [12-14]. Management of the very rare patients who have both T1DM and GHD raises questions of efficacy and safety of ...

ey0017.8-17 | Food for Thought | ESPEYB17

8.17. Plasma renin measurements are unrelated to mineralocorticoid replacement dose in patients with primary adrenal insufficiency

R Pofi , A Prete , V Thornton-Jones , J Bryce , SR Ali , Ahmed S Faisal , A Balsamo , F Baronio , A Cannuccia , A Guven , T Guran , F Darendeliler , C Higham , W Bonfig , L de Vries , TASS Bachega , MC Miranda , BB Mendonca , V Iotova , M Korbonits , NP Krone , R Krone , A Lenzi , W Arlt , RJ Ross , AM Isidori , JW Tomlinson

To read the full abstract: J Clin Endocrinol Metab. 2020; 105(1): dgz055. PMID: 31613957.Mineralocorticoid (MC) replacement therapy along with glucocorticoid (GC) replacement is crucial to avoid life-threating adrenal crises in Addison´s disease (AD) and in classical CAH (1–3). MC is administered with the aim of achieving plasma renin concentration (PRC) within the upper limit of ...